Seattle Genetics, Inc.: Expanded Sales on Their Way (FDA Willing)

Seattle Genetics, Inc.: Expanded Sales on Their Way (FDA Willing)

Seattle Genetics (NASDAQ: SGEN) reported second-quarter revenue and earnings numbers, but the conference call focused mostly on potential near-term revenue growth for the biotech's one approved drug, Adcetris, with one expanded indication under review at the FDA and another to be there shortly.

Metric

Q2 2017

Continue reading

Source: Fool.com